NCT06361199 is a Phase 1 clinical trial of Proximod in Rheumatoid Arthritis, sponsored by Longevity Inc..

Who is sponsoring NCT06361199?

NCT06361199 is sponsored by Longevity Inc..

What drugs are being tested in NCT06361199?

Interventions in NCT06361199: Proximod, Placebo.

What condition does NCT06361199 study?

NCT06361199 studies Rheumatoid Arthritis.

Is NCT06361199 still recruiting?

NCT06361199 is currently completed. Last updated 19 April 2024.

Last reviewed 2024-04-19 · How we verify

NCT06361199

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Proximod Pharmacokinetics in Healthy Subjects and Patients With Rheumatoid Arthritis

Completed Phase 1 Last updated 19 April 2024

What this trial tests

Phase 1 trial testing Proximod in Rheumatoid Arthritis in 22 participants. Completed in 8 October 2023.

Timeline

16 December 2021

Primary endpoint
16 February 2022

8 October 2023

Quick facts

Lead sponsor	Longevity Inc.
Phase	Phase 1
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	double
Primary purpose	treatment
Enrollment	22
Start date	16 December 2021
Primary completion	16 February 2022
Estimated completion	8 October 2023
Sites	1 location across China

Drugs / interventions tested

Proximod — full drug profile →
Placebo

Conditions studied

Rheumatoid Arthritis — all drugs for Rheumatoid Arthritis →

Sponsor

Longevity Inc. — full company profile →

Who can join

Adults 18 to 70, any sex, with Rheumatoid Arthritis. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The goal of this clinical trial is to evaluate the tolerability, pharmacokinetics and pharmacodynamics of Proximod in healthy subjects and patients with rheumatoid arthritis. The main questions it arms to answer are: 1. to evaluate the safety and tolerance of Proximod in health subjects after repeated doses. 2. to assess the pharmacokinetics and pharmacodynamics of Proximod in healthy subjects after repeated doses. 3. to evaluate the safety and tolerance of Proximod in patients with rheumatoid arthritis. 4. to evaluate the pharmacokinetics and pharmacodynamics of Proximod in patients with rheumatoid arthritis. Participants will receive test tablets or placebo at the indicated date and collect blood samples.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Evaluation of proximod, a selective agonist of sphingosine-1-phosphate receptor-1, in healthy volunteers and patients with rheumatoid arthritis: a phase 1, double-blind, randomised, placebo-controlled, ascending dose trial.
Zhang H, Li Q, Li C, Wu M, et al · · 2024 · cited 4× · PMID 39454617 · DOI 10.1016/s2665-9913(24)00199-1

Verify or expand the search:

Other trials of Proximod

Trials testing the same drug.

NCT06361186 — Proximod Pharmacokinetics In Healthy Subjects · Phase 1 · completed

Other recruiting trials for Rheumatoid Arthritis

Currently open trials in the same condition.

NCT07433335 — A Study to Assess the Safety and Tolerability of SR-878 in Patients With Rheumatoid Arthritis · Phase 1 · recruiting
NCT07491016 — Efficacy and Safety of Telitacicept Combined With Baricitinib for Refractory Rheumatoid Arthritis · recruiting
NCT07171983 — A Study to Evaluate the Safety, Tolerability, and Drug Levels of BMS-986454 in Participants With Rheumatoid Arthritis · Phase 1 · recruiting
NCT07246096 — Exploratory Clinical Study on the Safety and Efficacy of Anti- CD19/BCMA U CAR-T Cell Injection for the Treatment of Rel · EARLY_PHASE1 · recruiting
NCT07363590 — A Clinical Study of MK-1045 in People With Lupus or Rheumatoid Arthritis (MK-1045-004) · Phase 1 · recruiting

Other Longevity Inc. trials

Trials by the same sponsor.

NCT06361212 — Ethoximod Pharmacokinetics In Healthy Subjects · Phase 1 · completed
NCT06361186 — Proximod Pharmacokinetics In Healthy Subjects · Phase 1 · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06361199 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Longevity Inc.
Last refreshed: 19 April 2024

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06361199.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing